Oncopharmpod

Updates on billiary track cancer - a role for durvalumab? And pemigatinib - an approval in r/r myeloid/lymphoid neoplasms. Plus, an oral suspension of ibrutinib is approved and more evidence ICI combination should be given early in BRAF-mutated metastatic melanoma (rather than waiting until disease progression on TKIs)

The Landmarks of OncoPharm series return to discuss the now standard-of-care temozolomide + RT for glioblastoma multiforme (GBM) Stupp et al: https://www.nejm.org/doi/full/10.1056/NEJMoa043330 Effect of MGMT (the gene, not the band) on temozolomide effect (from the same NEJM issue) referenced, thought not discussed in this episode: https://www.nejm.org/doi/full/10.1056/NEJMoa043331

Dr. Amir Ali joins the Pod to cover the Foundations of OncoPharm on asparaginase products

In light of trastuzumab deruxtecan's approval for HER-mutated NSCLC, it's worthwhile to look back at the history of HER-targeted therapy in NSCLC and why/how targeted HER-mutated disease will affect practice.

New OS data is out for adjuvant atezolizumab in NSCLC - how does it compare to the original DFS data? Plus, lots of recent FDA expanded approvals to discuss.

An infamous study that led to a drug approval of limited benefit, but still made its way into an episode of Better Call Saul. Erlotinib + gemcitabine vs. gemcitabine: https://doi.org/10.1200/jco.2006.07.9525

Several recent large trials just released long term follow-up results on overall survival. We look at what how treatment principles may change based on these mature data. ECHELON-1 - Hodgkin's (A+AVD vs. ABVD) POLO - Pancreatic (olaparib maintenance vs. placebo) Keynote 355 - mTNBC (pembrolizumab + chemo vs. chemo) APHinity - adjuvant HER+ breast (pertuzumab/trastuzumab vs. trastuzumab) E1912 - CLL (ibrutinib/rituximab vs. FCR)

Discussion with a Lupus Nephritis patient (and Pharm.D. student) about manifestations and treatments of SLE and Lupus Nephritis.

Sifting through and summarizing lots of data on concomitant use of ICIs and PPIs. Suggested readings: 1. All the drugs: https://pubmed.ncbi.nlm.nih.gov/33154150/ 2. Pooled atezolizumab study: https://pubmed.ncbi.nlm.nih.gov/35183773/ 3. Clostridium butyricum may be a thing: https://pubmed.ncbi.nlm.nih.gov/35655708/ 4. AKI risk: https://doi.org/10.21873/invivo.12570 5. Is this all noise?: https://pubmed.ncbi.nlm.nih.gov/35280736/ 6. Abx & PPIs: https://doi.org/10.3389/fimmu.2021.716317

Acetaminophen (or paracetamol) & immune checkpoint inhibitors are ubiquitous in oncology practices. So, when new translational research suggests APAP may decrease the effectiveness - well that seems like something worth talking about. Impact of acetaminophen on the efficacy of immunotherapy in cancer patients: https://doi.org/10.1016/j.annonc.2022.05.010 Hepatotoxicity risk factors with ICIs: https://doi.org/10.1097/cji.0000000000000347

Febrile neutropenia updates on... Short duration antibiotics: https://doi.org/10.1016/S2352-3026(22)00145-4 Same-day pegfilgrastim: https://doi.org/10.2217/fon-2022-0365

Maya Leiva, PharmD, BCOP joins the Pod once again this Pride month to give us some LGBTQ clinical pearls on carboplatin dosing in trans patients and pregnancy/teratogenicity chemo counseling. LGBT Cancer Network: https://cancer-network.org

Highlights from ASCO's 2022 annual meeting.

Maya Leiva, PharmD, BCOP joins the Pod for Pride to give an overview of cancer screenings in the transgender population.

Looking at some interesting articles as possible predictors of what to expect next in NSCLC and AML. NADIM: https://pubmed.ncbi.nlm.nih.gov/?term=35576508 Ven + Intensive Chemo: https://doi.org/10.1016/S2352-3026(22)00100-4

By listener request, we discuss how to utilize our favorite guidelines.

A Foundation of OncoPharm: Docetaxel

The Landmarks of OncoPharm series returns to discuss 2 landmark studies (and 1 editorial) in head & neck cancer. Editorial: https://ascopubs.org/doi/pdf/10.1200/JCO.22.00274 EUORTC Study: https://www.nejm.org/doi/full/10.1056/NEJMoa032641 Intergroup Study: https://www.nejm.org/doi/full/10.1056/NEJMoa032646

The highlights, and only the highlights, of melanoma.

Treatment-free remission (TFR) rates in CML of close to 80% have recently been described (https://doi.org/10.1002/ajh.26550). The AGILE study. If you can't say anything nice. Checking back in on CHECKMATE 816 (neoadjuvant Nico-Chemo in NSCLC) and Keynote-177 (pembrolizumab in MSI-H/dMMR colorectal cancer).